Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 15, 2016

Primary Completion Date

November 22, 2021

Study Completion Date

May 1, 2025

Conditions
Prostate Cancer
Interventions
DRUG

Durvalumab

DRUG

Tremelimumab

Trial Locations (11)

V1Y 5L3

BCCA - Cancer Centre for the Southern Interior, Kelowna

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 2V7

Kingston Health Sciences Centre, Kingston

N6A 5W9

London Regional Cancer Program, London

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M4N 3M5

Odette Cancer Centre, Toronto

M5G 2M9

University Health Network, Toronto

S4T 7T1

Allan Blair Cancer Centre, Regina

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK